Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Type of Medium
Language
Subjects(RVK)
  • 1
    In: Cancer, Wiley, Vol. 110, No. 2 ( 2007-07-15), p. 244-254
    Abstract: This phase 2 randomized controlled trial evaluated the efficacy of neoadjuvant treatment with aromatase inhibitors compared with neoadjuvant chemotherapy in postmenopausal women with hormone receptor‐positive breast cancer. Aromatase inhibitors were well tolerated, and rates of overall objective response and breast‐conserving surgery were similar in both treatment groups.
    Type of Medium: Online Resource
    ISSN: 0008-543X , 1097-0142
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2007
    detail.hit.zdb_id: 1479932-7
    detail.hit.zdb_id: 2599218-1
    detail.hit.zdb_id: 2594979-2
    detail.hit.zdb_id: 1429-1
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, No. 15_suppl ( 2019-05-20), p. e12097-e12097
    Abstract: e12097 Background: Innovative advances in neoadjuvant systemic and targeted breast cancer therapy implicate surgical treatment in specific patient groups can be avoided. The core biopsy of the tumor bed and some diagnostic approaches (breast ultrasound, mammography, SPECT/CT) allow for precise evaluation of the treatment efficacy. Methods: This research started in our department in 2018, we picked two groups of 15 patients each treated for locally advanced TNBC or grade cT1-4N1-3M0 HER2-positive breast cancer: HER2+/ER+ or HER2+/ER- breast cancer. The TNBC group received 6 cycles of NACT of paclitaxel combined with doxorubicin and carboplatin AUC5. The HER2+ group received 4 cycles of АС polychemotherapy followed by 4 cycles of monochemotherapy with the docetaxel and 3-weekly trastuzumab. The HER2+ group is receiving adjuvant trastuzumab for up to one year, where ER-positive patients are also given hormone therapy with tamoxifen or aromatase inhibitors. The response to neoadjuvant treatment was assessed in all patients using standard two-dimensional mammography, ultrasound elastography, and SPECT-CT. The 12-point core biopsy of a tumor bed was performed in the operating room setting by previously marked tumor projections. Then, all patients underwent either breast-conserving surgery or mastectomy with immediate reconstruction with expander/implant. Results: After neoadjuvant therapy, in a group of 15 patients with TNBC in surgically obtained material, the pathologic complete response (pCR) was observed in 8 patients (53.33%), whereas residual disease was found in 7 (46.67%) patients. The core biopsy results showed no tumor cells in 10 (66.67%) patients, and were detected in 5 (33.33%) patients (p = 0.0011), the accuracy of the method in this group was 80%. The overall response rate in the group of 15 patients with HER2-positive breast cancer was 8 (53.33%) patients with residual disease and 7 (46.67%) patients with pCR. According to core biopsy, tumor cells were present in 3 (20%) patients and were absent in 12 (80%) patients (p = 0.0787). Conclusions: Avoiding surgical treatment through not less than 12-point core biopsy of a tumor bed in patients with complete regression after neoadjuvant therapy is a new trend in the treatment of breast cancer. Any new approach in this sphere requires a long-term elaboration, compliance with the safety principles, rethinking standard procedures and following-up patients.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2019
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, No. 15_suppl ( 2019-05-20), p. e23167-e23167
    Abstract: e23167 Background: In 2018, in the N.N. Petrov National Medical Research Center of Oncology, there was conducted a study of the effectiveness of a mental and social adaptation of patients to the disease and treatment in the framework of The International Classification of Functioning, Disability and Health (ICF). Methods: The patients with breast cancer (n = 28, mean age 31 ±7) were examined at the stages of diagnosis and admission to the hospital. The basis of the study is the «Narcissism Evaluation Test», EORTC QLQ-C30, as well as the following ICF domains: Body function - global psychosocial functions (b122), temperament and personality functions (b126), energy and drive functions (b130), sleep functions (b134), attention functions (b140), psychomotor functions (b147), emotional functions (b152), thought functions (b160), higher-level cognitive functions (b164). Activity and participation- doing housework (d640), family relationships (d760), intimate relationships (d770), acquiring, keeping and terminating a job (d845). Results: The increase in values (7.26–13.61; p 〈 0.05) on the “Depersonalization” scale indicates an attempt to dissociate from threatening processes in oneself by means of dissociation and splitting, to preserve the coherence of the personality structure. This tendency can be viewed as an attempt by the patient to deny that destabilization affects his personality and lifestyle, which leads to the experience of melancholia as an attempt at destruction of Self-Concept. Such reactions are classified by us within the framework of psychogenic, i.e. conditionally normal in the situation of cancer, however, it was shown that the pathology of “psychogeny” significantly reduces the quality of life and social adaptation. For example, in 11 patients, there is a decrease in the quality of life (62.85; p 〈 0.05), disturbed sleep, emotions, energy and drive functions (b134, b152, b130), and there are difficulties in the resumption of labor activities (d845). Conclusions: Experiencing the threat to the integrity of Self-Concept launches psychological defenses, as a result of which a rapid regression of Self-Concept occurs before the primary narcissism. Psychogenic reactions during pathologization contribute to the patient’s social and mental maladjustment.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2019
    detail.hit.zdb_id: 2005181-5
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: HERALD of North-Western State Medical University named after I.I. Mechnikov, ECO-Vector LLC, Vol. 14, No. 4 ( 2023-01-20), p. 33-42
    Abstract: BACKGROUND: BRCA-associated triple-negative breast cancer does not only have a better overall survival rate, but also a longer recurrence-free period in compatison to patients with sporadic breast cancer. BRCA-associated triple-negative breast cancer shows high sensitivity to chemotherapeutic agents, but the benefit of systemic neoadjuvant therapy for patients with tumor size T1 in triple-negative breast cancer is unclear. AIM: The aim of the study is to determine the recurrence rate in the patients with BRCA-associated triple-negative breast cancer and to determine the recurrence rate for the group of patients with tumor size T1, depending on the initial treatment. MATERIALS AND METHODS: The study includes the data of 129 patients diagnosed with BRCA-associated triple-negative breast cancer treated in the period from 2010 to 2022 at the Department of Breast Tumors of the N.N. Petrov National Medical Research Center of Oncology. All the patients have been divided into two groups depending on the initial treatment. Group I included 93 (72.1%) patients whose treatment was started with systemic neoadjuvant therapy, group II, whose initial treatment involved surgery, included 36 (27.9%) patients. RESULTS: In group I, the number of recurrences was 22 (23.6%), and in group II 6 (16.6%). Depending on the pathomorphological response to systemic neoadjuvant therapy, the patients of group I have been separated: in the group of patients with a complete pathomorphological response, the number of relapses was 6 (13.3%), and in the group of patients with a partial pathomorphological response 16 (33.3%). A comparative analysis of 2 groups with tumor size T1 has shown that in group I the number of patients with tumor size T1 was 11 (11.8%) cases, and in group II 16 (44.4%). Subgroup comparative analysis in group I, taking into account tumor size T1, has shown that recurrence has not been observed when a complete pathomorphological response was achieved in 8 (17.7%) patients, and in the group with partial pathomorphological response in 3 (6.25%) patients with tumor size T1. A relapse has been observed in 1 (2%) case. With clinical tumor size T1 (n = 16), there was no recurrence in group II. CONCLUSIONS: Patients diagnosed with BRCA-associated triple-negative breast cancer remain at a high risk of recurrence at a later stage of the disease, but this does not apply to patients with a tumor size T1 since the difference in relapse-free survival [AP1] between patients, whose treatment was started with neoadjuvant systemic therapy and patients, whose initial treatment involved surgery % with a clinical tumor size T1, is not confirmed.
    Type of Medium: Online Resource
    ISSN: 2618-9704 , 2618-7116
    Language: Unknown
    Publisher: ECO-Vector LLC
    Publication Date: 2023
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    In: The Breast, Elsevier BV, Vol. 24 ( 2015-11), p. S68-
    Type of Medium: Online Resource
    ISSN: 0960-9776
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2015
    detail.hit.zdb_id: 2009043-2
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 81, No. 4_Supplement ( 2021-02-15), p. PS9-62-PS9-62
    Abstract: Relevance: early breast cancer is detected in more than 60% of cases. Maintaining the quality of life of patients with early breast cancer at the highest possible level is a priority, along with the treatment of patients. Under a complex antitumor treatment as well as after its completion, more than 60% of patients with early breast cancer report the occurrence of functional disorders.An important aspect is to improve the effectiveness of the rehabilitation process of patients with early breast cancer taking into account scientifically-based and proven recommendations.Objective: to evaluate the event-free survival rate (EFS) of patients with EBC undergoing rehabilitation within a biopsychosocial approach.Materials and methods: 228 patients with breast cancer who received complex treatment from 2015 to 2019 were included in the study. The prospective part of the study included 114 patients with early breast cancer undergoing rehabilitation measures within the biopsychosocial approach. The control group which was selected retrospectively, using the method of "pairwise selection", included 114 patients with early breast cancer comparable in age, stage of the disease, volume of surgical treatment and menopausal status, undergoing physical and psychological rehabilitation prescribed by a doctor. Patients in both groups were stratified depending on preoperative chemotherapy. EFS was calculated over a 2-year follow-up period. Events that were censored were a disease progression, the appearance of metastases, the occurrence of another cancer, a new concomitant disease, an exacerbation of the concomitant pathology and death.Results: Rehabilitation measures within the biopsychosocial model improve the indicators of EFS in the group of patients with EBC: EFS was 18.3 months against 14.5 months in the control group (HR=0.91, 95% CI [0.83; 0.99]; p=0.0034). In a multi-factor analysis the key factors affecting EFS were neoadjuvant chemotherapy (HR=0.79, 95% CI [0.69; 0.94] ; p=0.0025), age (HR=0.87, 95% CI [0.71;1.09]; p=0.0027) and menopausal status (HR=0.85, 95% CI [0.84; 0.95] ; p=0.0022) (table 1). Conclusions: Rehabilitation measures within the biopsychosocial model improve the indicators of EFS in the group of patients with early breast cancer, the key factors affecting EFS were neoadjuvant chemotherapy, age and menopausal status. Table 1 Multi-factor analysis of event-free survival of patients with early breast cancer in the group of biopsychosocial model of rehabilitation versus control group.CharacteristicNumber of patientsHR (95% CI)Preoperative chemotherapyyes1520,84 (0,77; 1,1)no760,79 (0,69; 0,94)Menopauseyes1300,84 (0,77; 1,04)no980,85 (0,84; 0,95)Age group25-44610,87 (0,71; 1,09)45-601030,89 (0,74; 1,1)61-75641,01 (0,82; 1,24)EventDisease progression281,11 (0,86; 1,26)Exacerbation of the concomitant pathology160,83 (0,74; 0,96) Citation Format: Valeria Kluge, Tatiana Semiglazova, Petr Krivorotko, Elena Melnikova, Vladislav Semiglazov, Kristina Kondrateva, Svetlana Nazarova, Margarita Tynkasova, Bahtiyar Adhamov, Roman Pesotsky, Konstantin Zernov, Valentina Chulkova, Boris Kasparov, Denis Kovlen, Vladimir Semiglazov, Alexey Belyaev. Biopsychosocial approach in the rehabilitation of patients with early breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS9-62.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2021
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 83, No. 5_Supplement ( 2023-03-01), p. P3-04-12-P3-04-12
    Abstract: Background. Surgical method is fundamental in complex and combined approach of the treatment of the early breast cancer. It is a common fact, that purity of the resection margin is the main indicator of oncological safety of the breast-conserving surgery (BCS). The presence of tumor cells in examined margin is one of the predictors of the development of local recurrence after BCS with breast cancer. Currently the necessity of searching for adequate and quick method of intraoperative valuation of the state of the resection margin is kept. Intraoperative valuation of the resection margin state with the usage of digital two-point sectorography (Faxitron BioVision) appeared as the alternative of urgent histological test, providing the optimum size of the information about adequacy of the carried out surgical treatment. Objective – to evaluate diagnostic features of the digital two-point sectorography Faxitron BioVision in the intraoperative valuation of the resection margin status after the conducted surgical treatment in comparison with planned histologic study. Materials and methods. 368 conducted conservative surgeries were analyzed, patients were divided in two groups depending on carrying out of non-adjuvant chemotherapy (NAC). The first group of patients included 236 patients, who didn`t received NAC before operative treatment stage; second group included 132 patients, who received NAC. Subset analysis of detection rate of the positive resection margin was carried out with the usage of the intraoperative valuation of the resection margin on the X-ray apparatus Faxitron BioVision or without carrying out this method. After each BCS conducted when planned histologic study resection margin were tested for the presence of the tumor cells and the frequency of carrying out of reoperations when positive margin were found. Results. From 368 tested anatomic medications after BCS positive resection margin (R1) is found in 25 cases, which is 6,8 %. From 236 patients of the first group after BCS R1 is found in 20 cases, which is 8,5 %; from 132 conducted operations in the second group in 5 (3,8%) сases – the presence of R1 is found. Reoperations were conducted in 13 cases, when repeated pathomorphological study tumor cells found in 3 cases in the subgroup, which didn`t receive intraoperative valuation on the X-ray apparatus Faxitron BioVision. Conclusion. Assessing the results of our study we can make a conclusion about the positive experience of conducting of BCS and intraoperative evaluation of conservative surgery and intraoperative valuation with the usage of the digital two-point sectorography (Faxitron BioVision) and low frequency of positive margin (3,8%) in comparison with refusal from carrying out of this method (8,5%). Citation Format: Petr Krivorotko, Yana Bondarchuk, Elena Zhiltsova, Roman Pesotsky, Alexander Emelyanov, Tengiz Tabagua, Larisa Gigolaeva, Sergey Yerechshenko, Alexander Komyakhov, Kirill Nikolaev, Konstantin Zernov, Ruslan Paltuev, Viktoria Mortada, Tatiana Semiglazova, Diana Enaldieva, Nikolay Amirov, Valentin Channov, Antonina Chernaya, Roxanne Ulyanova, Anna Artemyeva, Vladimir Semiglazov, Vladislav Semiglazov. Intraoperative valuation of the resection margin with the usage of digital two-point sectorography (Faxitron BioVision) [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P3-04-12.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2023
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 4_Supplement ( 2020-02-15), p. P5-14-23-P5-14-23
    Abstract: Background: Alopecia is one of the most frequent adverse event of chemotherapy (CHT) in patients with breast cancer (BC). Alopecia causes many unpleasant feelings, as well as emotional disorders, including depression, especially in women Aim: to improve the quality of life among BC patients undergoing CHT. Materials and methods: alopecia prevention procedures were performed by the Cold Caps and Scalp Cooling Systems during various regimens of CHT for 180 BC patients. The mean age of the BC patients was 43 y.o. (from 21 to 73). The alopecia prevention procedure was performed during CHT and included 3 steps: 1. The preventive cooling cycle took 20-30 minutes to achieve required temperature before proceeding medications. 2. The cooling cycle last during whole CHT. 3. The cooling cycle were continued after CHT and took from 60 to 120 minutes. The duration of post-CHT cycle was dependent on the type of drug and the period of excretion. Patients received various regimens of CHT, including: antracyclins (47%), taxanes (32%), Cisplatin (5%), Gemcitabine (3,5%), AT (3,5%), CP (9%). Local hypothermia during various regimens of CHT (n= 988). Regimens of CHTPatients, n=180Cycles, n= 988n cycles per patientАT (doxorubicin + paclitaxel)6355 (2-6)АС (doxorubicin + cyclophosphamide)864474 (2-6)СР (Carboplatin+ Paclitaxel)15201 (1-4)Paclitaxel584407 (4-12)Cisplatin9302 (2-4)Gemcitabine6162 (2-4) Alopecia degree evaluated based on СТСАЕ 4.0: I degree - hair loss of & lt;50% of normal for that individual that is not obvious from a distance but only on close inspection; a different hair style may be required to cover the hair loss but it does not require a wig or hair piece to camouflage. II degree - hair loss of & gt;=50% normal for that individual that is readily apparent to others; a wig or hair piece is necessary if the patient desires to completely camouflage the hair loss; associated with psychosocial impact. Results: Among BC patients who were given antracyclins (n=86), 62 (72%) had I degree alopecia, 24 (28%) - II degree alopecia. Among patients who were given taxanes (n=58), 56 (96%) suffered from I degree alopecia, in 2 (4%) of them developed II degree alopecia. Patients who received treatment with Cisplatin (n=9), 7 (78%) of them had I degree alopecia and 2 - II degree alopecia (22%); patients with gemcitabine-based CHT (n=6), suffered from I degree alopecia in 100%. Patients with AT (n=6), had I degree alopecia in 3 (50%) patients, 3 (50%) suffered from II degree alopecia. In regimens like CP (n=15), 8 (53%) had I degree alopecia, 7 (47%) - II degree alopecia. Side effects after procedure: 5 (2,8%) patients had headaches, procedure was discontinued for 3 (1,7%) patients because of intolerance to low temperatures. Conclusions: hypothermia of the hairy part of the head is an effective method of preventing alopecia among BC patients during chemotherapy with antracyclins (72% of cases), taxanes (96%), Cisplatin (78%) and with gemcitabine (100%). Citation Format: Veronika Klimenko, Tatiana Semiglazova, Boris Kasparov, Anton Krutov, Margarita Zernova, Kristina Kondrateva, Valeria Kluge, Evgenia Kharchenko, Artem Poltoratsky, Karina Khidishyan, Vladislav Semiglazov, Roman Donskih, Petr Krivorotko, Vladimir Semiglazov, Aleksey Belyaev. Preventing alopecia caused by chemotherapy among patients with breast cancer efficacy of applying the cooling hood [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-14-23.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    Autonomous non-profit scientific and medical organization - Questions of Oncology ; 2023
    In:  Voprosy Onkologii Vol. 69, No. 2 ( 2023-04-30), p. 268-274
    In: Voprosy Onkologii, Autonomous non-profit scientific and medical organization - Questions of Oncology, Vol. 69, No. 2 ( 2023-04-30), p. 268-274
    Abstract: Introduction. It is essential to accurately identify HER2-amplified tumors for effective classification and treatment of breast cancer patients. The most precise method for detecting HER2 gene amplification is fluorescence in situ hybridization (FISH) testing. When tumor status is uncertain in IHC analysis, FISH testing becomes necessary for proper classification into the category of triple-positive carcinomas. Data on the biology of such tumors and their response to therapy are limited and inconsistent, which makes this topic an interesting area for further research. Aim. To characterize the distribution of HER2 FISH testing results in ER+/PR+ breast cancer. Materials and methods. 247 samples of ER+/PR+ breast tumors were studied. The HER2 gene amplification was analyzed using the fluorescence in situ hybridization (FISH) method. The average number of signals from the centromere of chromosome 17 (CEN17) and HER2 gene per nucleus, as well as their ratio, were calculated. The results were grouped according to the level of amplification. Results. In the triple-positive carcinoma group, the distribution of amplification groups was as follows: group 1 (HER2/CEN17 signal ratio ≥ 2.0, HER2 signals/cell nucleus ≥ 4.0) — 91.7 %, group 3 (HER2/CEN17 signal ratio 〈 2.0, HER2 signals/cell nucleus ≥ 6.0) — 7.3 %, group 4 (HER2/CEN17 signal ratio 〈 2.0, HER2 signals/cell nucleus 4.0 - 6.0) — 0.91 %. "Non-classical" FISH results were found in 92.8 % of cases. In the ER+/PR+/HER2- carcinoma group, the frequency of "non-classical" results was 30.4 %. Сonclusion. In the triple-positive breast cancer group, the frequency of "non-classical" FISH results is 9 times higher than the frequency of such results in the general testing cohort (according to literature data) and 2 times higher than the frequency of such results in the ER+/PR+/HER2- cancer group. These results may be due to bidirectional crosstalk between the estrogen receptors and HER2 signaling pathways and may determine the biology of this group of tumors. Limited data on the interpretation and clinical significance of "non-classical" FISH results make it difficult to choose drug therapy for patients with breast cancer and determine the prognosis of the disease.
    Type of Medium: Online Resource
    ISSN: 0507-3758
    URL: Issue
    Language: Unknown
    Publisher: Autonomous non-profit scientific and medical organization - Questions of Oncology
    Publication Date: 2023
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    Autonomous non-profit scientific and medical organization - Questions of Oncology ; 2023
    In:  VOPROSY ONKOLOGII Vol. 69, No. 3 ( 2023-06-30), p. 571-584
    In: VOPROSY ONKOLOGII, Autonomous non-profit scientific and medical organization - Questions of Oncology, Vol. 69, No. 3 ( 2023-06-30), p. 571-584
    Abstract: В марте 2022 г. исполнилось 95 лет со дня основания Ленинградского института онкологии (ЛИО), носящего имя отца российской онкологии Николая Николаевича Петрова. Заведующим женского отделения был назначен Семен Абрамович Холдин, один из наиболее близких помощников, а позже — соратников Н.Н. Петрова. С.А. Холдин являлся признанным авторитетом в вопросах диагностики, клиники и лечения опухоль прямой и толстой кишки и опухолей молочной железы. С.А. Холдин был основоположником в стране использования расширенных подмышечно-грудинных мастэктомий. Одним из главных последователей С.А. Холдина был доктор медицинских наук Дымарский Леонид Юльевич (1924-1984). Работая в I хирургическом отделении под руководством С.А. Холдина, он провел большую исследовательскую работу по лимфогенному метастазированию рака молочной железы, дает клиническую и анатомическую характеристику путей лимфогенного метастазирования, особенностей развития течения и лечения двухстороннего рака молочных желез. В относительно короткий с точки зрения истории период (1975-1985 г.) произошел коренной переход 1-го отделения от одного хирургического лечения (мастэктомия, брюшно-анальные резекции) к комбинированному и комплексному лечению. В отделении опухолей молочной железы института им. Н.Н. Петрова был взят курс на выполнение органосохраняющих операций и проведение международно признанных рандомизированных клинических испытаний адъювантной и неоадъювантной цитотоксической химиотерапии, эндокринотерапии, таргетной терапии и иммунотерапии РМЖ. Одновременно с разработкой органсохраняющего лечения в отделении проводятся интенсивные исследования, биологических характеристик опухолей молочной железы, молекулярно-генетических и иммунологических маркеров предиктивных и прогностических маркеров чувствительности к цитотоксической химиотерапии, эндокринотерании, таргетной терапии и иммунотерапии. Как и во времена Семена Абрамовича Холдина такие исследования возможны только в тесной кооперации с другими подразделениями и отделениями нашего центра им Н.Н. Петрова (отдел патоморфологии опухолей, лаборатория молекулярной генетики, иммунологический отдел, лаборатория эндокринологии, отдел лучевой диагностики, отдел радиотерапии, а также в сотрудничестве с лучшими зарубежными онкологическими центрами.
    Type of Medium: Online Resource
    ISSN: 0507-3758
    URL: Issue
    Language: Unknown
    Publisher: Autonomous non-profit scientific and medical organization - Questions of Oncology
    Publication Date: 2023
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages